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Abstract
Hyaluronan (HA) shows promise for detecting cancerous change in pleural effusion and urine. However, there is uncertainty about the
localization of HA in tumor tissue and its relationship with different histological types and other components of the extracellular matrix,
such as angiogenesis. We evaluated the association between HA and degree of malignancy through expression in lung tumor tissue
and sputum. Tumoral tissue had significantly increased HA compared to normal tissue. Strong HA staining intensity associated with
cancer cells was significant in squamous cell carcinoma compared to adenocarcinoma and large cell carcinoma. A significant direct
association was found between tumors with a high percentage of HA and MVD (microvessel density) in tumoral stroma. Similarly
significant was the direct association between N1 tumors and high levels of HA in cancer cells. Cox multivariate analysis showed
significant association between better survival and low HA. HA increased in sputum from lung cancer patients compared to cancer-free
and healthy volunteers and a significant correlation was found between HA in sputum and HA in cancer tissue. Localization of HA in
tumor tissue was related to malignancy and reflected in sputum, making this an emerging factor for an important diagnostic procedure
in patients suspected to have lung cancer. Further study in additional patients in a randomized prospective trial is required to finalize
these results and to validate our quantitative assessment of HA, as well as to couple it to gold standard sputum cytology.
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Introduction
Lung cancer (LC) is the major cause of death among
other types of cancer in the world (1). Since the last record,
LC represented 224,210 new cases with 159,260 deaths
according to SEER Cancer Statistic Review (2). Another
concerning fact about LC is the mortality rate, which is
responsible for 75.2 deaths/100,000 men and 52.3 deaths/
100,000 women in the United States (2). In Brazil, the
National Institute of Cancer (INCA) estimated 27,330 new
cases of LC in 2014 (http://www.inca.gov.br/estimativa/2014/).
The highmortality rates are closely related to the diagnosis
that is usually performed in the later stages of the disease
when the treatment options are only palliative (3). The high
incidence and mortality of patients with LC indicate
urgency for new diagnostic procedures and prognostic
factors for early detection of recurrence and shortening of
a patient’s life. In this context, sputum is an attractive
potential source of biomarkers for LC because it can be
obtained noninvasively and may represent the field of
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injury. Consequently, many research groups have
been examining sputum for potential biomarkers, but,
to date, there are no definitive data indicating that
sputum biomarkers are sufficiently sensitive and specific
to reliably predict which high-risk patients will go on to
develop LC.
Thus, our group studied molecular or other markers in the
primary tumor as well as the stroma tissuemilieu to determine
what might relate to tumor recurrence and shortened survival
(4-6). Because cell-extracellular matrix interactions participate
in several steps required for tumor cell invasion and formation
of metastases, a group of glycosaminoglycans has been
targeted as a potentially useful tumor marker (4,5). Among
these glycosaminoglycans, hyaluronan (HA) has shown
promise. HA is a linear polysaccharide chain, composed of
repeating disaccharide units of N-acetyl-D-glucosamine-b
(1,4)-D-glucuronic acid-b (7,8), which exists in both a high
molecular mass form (1-66106 Da) and a polydisperse lower
molecular mass form (0.1-0.56106 Da), with the latter
predominating under neoplastic conditions (9). HA has diverse
biological functions in migration and proliferation (10), cell
growth, and differentiation (11), as well as in disease
progression (12). Polymerization of HA is regulated by the
action of one or more of three synthases (HAS1, HAS2, and
HAS3) (13) and the hyaluronidases (HYAL1 and HYAL2),
present in various tissues including the lung, are responsible
for its degradation (14). Degradation products of HA may
enhance tumor growth by stimulating malignant neovascular-
ization (15). A biotinylated HA probe has shown more
sensitivity than gold standard cytology to detect malignant
changes in pleural effusion of mesothelioma (16-20) and urine
from patients with urologic cancer (21-24), with an impact on
prognosis. In some studies, staining for HA in formalin-fixed
paraffin-embedded (FFPE) tissue has also been found to be
significantly associated with survival (25-29), but there has
been uncertainty about localization of HA in tumor tissue and
its relationship with different histological types and other
components of the extracellular matrix, such as angiogenesis,
aswell as impact ofmalignancy on prognosis.More important,
to our knowledge HA has never been evaluated in the sputum
from LC patients.
In the light of previous data, the first step of this work was
to evaluate qualitative and quantitative distribution of HA in
FFPE tumor tissue and its relationship with histological types
and angiogenesis as indicators of malignancy. Hypothesizing
an impact of these indicators on prognosis of patients, in a
second step we evaluated the reflection of these changes in
frozen sputum and cancer tissue specimens. We found that
HA expression in tissue is an indicator of malignancy and has
a relationship with sputum from patients with LC.
Patients and Methods
Sputum collection
This study was approved by the Institutional Review
Board of the Hospital das Clı´nias, Faculdade de Medicina,
Universidade de Sa˜o Paulo (#256/10). Spontaneous
sputum was collected from 115 consecutive patients
(mean age 63±10 years; 76 male, 39 female), just prior
to bronchoscopy, attending the Instituto do Cancer do
Estado de Sa˜o Paulo and the Hospital do Cancer de
Barretos for suspected LC. Informed consent to provide a
sputum sample was obtained from each patient at a
previous clinical appointment. LC was subsequently
confirmed through final clinical diagnosis in 90 patients
(mean age 61; 59 male, 31 female) whose sputum was
included in this study. Table 1 summarizes the clinical
features of these 90 LC patients. They included 37 current
smokers (median packs/year=48), 38 ex-smokers (med-
ian packs/year =39), and 15 never smokers. The final
stages (tumor, node, metastasis: TNM) for these patients
were T1 (n=8), T2 (n=24), T3 (n=22), T4 (n=36), N0
(n=14), N1 (n=76), M0 (n=46), and M1 (n=44).
Histological diagnosis included 32 squamous cell carci-
noma (SqCC), 56 adenocarcinoma (AD), and 2 large cell
carcinoma (LCC). The median follow-up for these patients
was 27 months, and 32 patients were censored for
survival analysis at the last time of follow-up.
Sputum induction
Sputum was also collected from 25 patients classified
as cancer-free and 15 as healthy volunteers. All 15
healthy volunteers, selected during an investigation for
non-pulmonary diseases, such as ophthalmology or
endocrinology, and the patients selected underwent
sputum induction by 3 inhalations of 4% hypertonic saline
for 7 min each (30). The sputum samples were stored on
ice during collection, and were macroscopically separated
from the saliva in sterile petri dishes with the help of a
needle. After separation, the sputum samples were stored
at –806C until HA analysis.
The sputum samples were thawed and incubated with
7 M urea at 606C, until the complete breakdown of the
sputum’s hydrophobic associations. The protein concen-
tration of each sample was measured using a NanoDrop
2000c (Thermo Scientific, USA). After protein concentra-
tion analysis, the samples were incubated with a
proteolytic enzyme for 18 h at 606C, and HA chains were
diluted (1:100) in blocking buffer [0.05 M Tris-HCl, pH 7.4,
1% bovine serum albumin (BSA)].
Frozen lung tissue
Forty-six patients (mean age 65; 25 male, 17 female)
of the 90 with confirmed LC were clinically staged as T1-
4N1M0 and were considered to have tumors potentially
curable by surgical resection. These 46 lung specimens
were included in the study for biochemical analysis,
histological hematoxylin and eosin staining, and immuno-
histochemical and immunofluorescence analyses. Clinical
staging used routine chest X-ray, bronchoscopy, compu-
terized tomography of thorax and upper abdomen,
abdominal ultrasound, and bone scan. Mediastinoscopy
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and lymph node biopsy were additionally performed on
patients whose lymph nodes had a short axis diameter of
.1 cm. They included 25 current smokers (median
packs/year=48), 6 ex-smokers (median packs/year=39),
and 15 never smokers. The final pathological stages
(TNM) of these patients included T1 (n=11), T2 (n=24),
T3 (n=7), T4 (n=4), N0 (n=25), N1 (n=21), M0 (n=46),
and M1 (n=0). The tumors were classified as SqCC
(n=13), AD (n=27), and LCC (n=6). Other detailed
information about these patients is shown in Table 1.
Tumor tissue and normal lung tissue from the
resected specimens were examined during the first
15 min after resection; the tumor was localized macro-
scopically, and 1-cm3 fragments of tumor and normal
lung tissue were stored in liquid nitrogen at –1706C. A
mirror fragment was fixed in formalin, embedded in
paraffin, and stained with hematoxylin and eosin for
histological evaluation, in order to guarantee the tumor
representation. Two investigators (MPR and VLC)
reviewed and verified the histological diagnosis in
non-small-cell LC to be SqCC, AD, and LCC, classified
according to the recently published classification for LC
(31), and selected a sample of the paraffin-embedded
tumor for immunohistochemical scoring and analyses
of the cell-specific localization by immunofluorescence
and confocal microscopy.
Biotinylated HA probe in frozen sputum and lung
tissue
To determine the levels of HA present in the tumoral
and normal lung samples collected, the tissues were
dehydrated with acetone, dried, weighed, and incubated
with a proteolytic enzyme for 18 h at 606C. The HA chains
were diluted (1:100) in blocking buffer (0.05 M Tris-HCl,
pH 7.4, 1% BSA). Determination of HA was performed
using the same ‘‘ELISA-like’’ fluorometric assay as used
on the sputum (32). The dry tissue samples were assayed
in triplicate. The levels HA found in the tissue specimens
is reported using the dry tissue weight (mg/g of dry tissue)
as reference.
Biotinylated HA probe and microvessels in FFPE lung
tissue
HA quantification in situ was done in FFPE sections of
LC and normal tissue. All sections underwent the
following treatment: a) inhibition of endogenous perox-
idase activity with 3% hydrogen peroxidase in phosphate-
buffered saline (PBS); b) blockage of nonspecific binding
sites with 1% BSA in PBS; c) incubation in HA-biotinylated
probe solution diluted 1:600 in 1% BSA/PBS for 1 h at
46C; d) elimination of endogenous biotin in tissue sections
by incubation in streptavidin peroxidase solution; and e)
visualization of peroxidase activity through incubation with
Table 1. Clinical features of lung cancer patients.
Sputum analysis (n=90) Tissue analysis (n=46)
Age 61 (37-89) 65 (44-84)
Gender (M/F) 59/31 25/17
Smoking history
Yes 37 25
No 15 15
Ex-smoker 38 6
Stage T
1 8 11
2 24 24
3 22 7
4 36 4
Stage N
0 14 25
1 76 21
Stage M
0 46 46
1 44 0
Histologic type
Squamous cell carcinoma 32 13
Adenocarcinoma 56 27
Large cell carcinoma 2 6
Follow-up (months) 27 (7-88) 27 (7-88)
Patients censored for survival analysis
at last time of follow-up
32 32
Data are reported as number or median and range.
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chromogenic diaminobenzidine (Sigma, USA) and 0.03%
hydrogen peroxidase. Brownish staining was considered
evidence of HA expression by the cells.
Microvessel evaluation was done by immunostaining
using an anti-CD34 monoclonal antibody (Novocastra
Laboratory, UK; dilution 1:600), pressure-cooking antigen
retrieval, biotinylated rabbit anti-mouse IgG (Dako Corp.,
USA; dilution, 1:400), streptavidin combined in vitro with
biotinylated horseradish peroxidase (Dako Corp.; dilution,
1:1000), diaminobenzidine tetrahydrochloride, and coun-
terstaining with hematoxylin. Brownish cytoplasmic stain-
ing was considered to be evidence of the antigen
expression by cells.
Evaluation of HA and microvessel staining
We evaluated the HA and microvessel staining in
nonneoplastic cells, LC cells, and tumor stroma by image
analysis. The HA and microvessel quantification was
done by recording histological images with a Nikon
Eclipse 50i camera (Japan) attached to the microscope,
using a 406 objective. The staining measurements were
done by computer analysis, using the Image Pro-Plus 6.0
software (Media Cybernetics, USA). All the analyses were
performed at a magnification of 4006.
Staining for HA was noted on the cell surface and in
the cytoplasm of cancer cells and in peritumoral stroma,
whereas microvessel staining was noted on endothelial
cells present in tumoral and peritumoral stroma. The
percentage of stained tumor parenchyma was evaluated
using a continuous threshold (0%-100). For statistical
purposes, cases were further divided into two groups
according to a receiver operation characteristic (ROC)
curve as follows: expression of HA was considered high if
>48% of the tumoral area showed a persistent HA signal,
whereas cases having ,48% staining were classified as
low. This cut-off level allowed the most clear-cut separa-
tion between high and low expressors. The intensity of HA
staining in cancer cells and in peritumoral stromal tissue
was classified as weak (,48 and ,84%, respectively, of
stromal tissue/cancer cells with intense signal) or strong
(>48 and >84%, respectively, of stromal tissue/cancer
cells with intense signal). Equally, the intensity of
microvessel staining in tumoral stroma and peritumoral
stroma was classified as weak (,33 and ,26%,
respectively, of peritumoral stroma/tumoral stroma with
intense signal) or strong (>33 and >26%, respectively, of
peritumoral stroma/tumoral stroma with intense signal).
HA and microvessel colocation
HA and microvessel colocation was evaluated in
tumor stroma after immunofluorescence staining using
confocal microscopy. Pressure-cooking antigen retrieval
was performed followed by incubation with mouse
polyclonal anti-human CD34 antibody (1:50; Santa Cruz
Biotechnology, Inc., USA) and an HA-biotinylated probe
solution (1:150; kindly donated by Dr. Nader from the
Departamento de Bioquı´mica, Disciplina de Biologia
Molecular, Universidade Federal de Sa˜o Paulo, Brazil).
For negative controls, sections were incubated with PBS
instead of the primary antibody. The sections were
then incubated with the secondary antibodies, i.e., goat
anti-mouse ALEXA 488 and streptavidin ALEXA 546
(Invitrogen, USA; dilution 1:400) for 3 h. Nuclear staining
was done with 49,6-diamidino-2-phenylindole, dihy-
drochloride for 30 min (Invitrogen; 1:300). Images were
obtained using a Zeiss LSM-410 laser-scanning confocal
microscope (Carl Zeiss, Germany). Serial optical sections
were performed with the Simple 32 C-imaging computer
software (LSM Image Browser software, Carl Zeiss). Z-
series sections were collected at 0.6 mm with a660 Plan
Apo lens and a scan zoom of 62. All images were
collected at the same photomultiplier tube settings.
Images were processed and reconstructed using the US
National Institutes of Health Image software.
Statistical analysis
Statistical analysis was performed using SPSS 18.0
(SPSS Inc., USA). When necessary, the variables were
analyzed with the Kolmogorov-Smirnov test to determine
the normality pattern. Mann-Whitney and Kruskal-Wallis
tests were used to analyze the sputum from 90 patients
with LC, 25 cancer-free patients, and 15 healthy volun-
teers. When nonparametric methods were used, simulta-
neous comparisons of the confidence levels were
corrected with Bonferroni’s post hoc test. The Mantel-
Haenszel test or Pearson’s x2 test were used to clarify the
relationship between HA and microvessel staining with the
tissue and the sputum variables studied. ROC curves were
developed for determining the optimal cut-off limits that
yielded the best possible sensitivity and specificity values.
Data on various biochemical, surgical, and pathological
parameters, as well as HA and microvessel staining
inferences, were analyzed by the Cox proportional hazards
model, using single-variable analysis (univariate analysis).
Stratified Kaplan-Meier analyses were performed on the
variables found to be significant in the multivariate Cox
proportional hazards model. The results with P less than or
equal to 0.05 were considered to be significant.
Results
Cancer-free patients and healthy volunteers had a
median age of 65 years; there was no significant
difference in age between the groups. There were fewer
females in the cancer-free group (n=17) than in the
malignant group (n=31) or the LC group (Table 1).
Figure 1 shows normal lung, SqCC, AD, and LCC
stained by hematoxylin and eosin (A, F, K, P), biotinylated
HA probe (B, G, L, Q), immunofluorescence double
staining for HA and microvessel colocalization at confocal
microscopy (D, I, N, S), and quantification of HA in FFPE,
respectively.
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Normal lung (Figure 1A) showed a strong HA signal at
the epithelial cell-extracellular matrix interface (Figure 1, B
and C), coincident with regular microvessel staining (C)
and absence of colocalization at confocal microscopy (D).
A significant increase in the HA signal was found in tumor
tissue compared to normal tissue (P,0.05; Figure 1E).
SqCC (F) showed abundant HA signals on the cancer
cell-stroma interface (G) coincident with prominent micro-
vessel staining (H) and identical colocalization at confocal
microscopy (I). Strong HA staining intensity associated with
cancer cells was significant in 32.1% of SqCC compared to
17.9% of AD and 0.0% in LCC (P,0.001; Table 2; Figure 1J).
ADs (Figure 1K) revealed strong stromal HA staining
in remarkable contrast with the HA-poor tumor cells in
ADs (L). The foci of strong HA intensity in the stroma was
coincident with foci of microvessel staining (M) and foci of
colocalization at confocal microscopy (N). Furthermore,
AD more often showed a lower percentage of HA-positive
cancer cells (35.7% of cases) than LCC (14.3% of cases)
or SqCC (0% of cases; P,0.001; Figure 1O). The cancer
stroma HA staining intensity was similar among the three
histological types (P=0.3; Table 2).
For LCC (P), the HA signal in tumor cells was very
poor or absent and contrasted with the foci of strong
intensity in stroma (Q), coincident with focal microvessel
density (R) and focal colocalization at confocal micro-
scopy (S). The poor qualitative distribution of HA in tumor
tissue overlapped with the very low HA intensity of
staining after quantitation (Figure 1T).
Table 2 shows the morphometric results for micro-
vessels in cancer stroma and normal tissue stratified
according to histological type. Microvessels were sig-
nificantly higher in AD (32.3%) and LCC (16.1%)
compared to SqCC (3.2%; P=0.02). No difference in
microvessels was observed in normal lung stroma of the
three histological types.
A significant direct association was found between
tumors with a high percentage of HA and MVD in tumor
Figure 1. Strong hyaluronan (HA) signal at the epithelial cell-extracellular matrix interface (B) in normal lung (A), coincident with regular
microvessels staining (C), absence of colocalization at confocal microscopy (D) and low signal when compared to tumoral tissue (E).
High expression (> 48%) of HA in squamous cell carcinoma (SqCC) (F) on cancer cells-stroma interface (G), coincident with high
microvessel (>33%) staining foci (H), identical colocalization at confocal microscopy (I) and higher signal when compared to normal
tissue (J). HA-negative in normal lung (K) and cells of adenocarcinoma (AD) (L); note the strong HA staining in tumor stroma (L),
coincident with microvessels staining (M), foci of colocalization at confocal microscopy (N) and higher expression compared to normal
tissue (O). Very poor signal in normal lung (P) and in large cell carcinoma (LCC) (Q); note strong HA foci staining (Q), coincident with
focal microvessels density (R), focal colocalization at confocal microscopy (S) and low signal when compared to normal tissue (T).
Arrowheads indicate stromal tissue; asterisks indicate carcinoma cells. H&E: hematoxylin and eosin; MVD: microvessel density
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stroma (R=0.6; P=0.02). Similarly significant was the
direct association between tumors at the N1 stage and
high levels of HA in cancer cells (R=0.31; P=0.05). In
addition, tumors in the T4 stage presented positive
association with a high percentage of HA-positive cancer
cells (R=0.80; P=0.01).
At the end of the follow-up, 32 patients of 46 (69.5%)
who underwent surgical resection died because of LC.
Univariate survival analysis showed that the significant
predictors of overall survival (OS) were N stage (x2=4.3;
P=0.03) and HA expression in cancer cells (x2=5.2;
P=0.02). A high percentage of HA-positive cells pre-
dicted a shortened disease-free survival [n=11 (47.8%),
P=0.02] in univariate analysis together with stage
(P=0.02). However, among ADs, there was a trend
toward poor OS, with tumors showing a high percentage
of cancer cell-associated HA (P=0.09). Comparative Cox
multivariate analysis controlled by gender, age, and AD
showed a significant association between better survival
and low cancer cell-associated HA sign (HR=0.08;
P=0.03). We ranked the cases according to ROC curve
into two groups with distinctly different average survival
times as illustrated by Kaplan-Meier plots in Figure 3. The
group with ,692.1 mg/mg HA appears as the top curve,
and their median survival time was 72 months. Those with
>692.1 mg/mg HA (bottom curve) had a median survival
time of just 52 months after surgery (log rank=5.3;
P=0.02).
Table 2 shows the concentration levels of HA found in
normal and cancer lung tissue surgically resected from 46
patients with LC. HA concentration levels were signifi-
cantly increased in tissue from patients with LC compared
to normal lung tissue (P,0.001). HA concentration levels
increased seven-fold in cancer tissue compared to normal
lung tissue. Concentration levels of HA were significantly
higher in lung tissue from patients with SqCC than AD and
LCC (P=0.01; Table 2), coincident with the qualitative
and quantitative immunoexpression observed in FFPE
(Figure 1, G and J).
The concentration levels of HA in sputum obtained
from 90 patients with LC, 25 cancer-free patients, and 15
healthy volunteers are shown in Table 3. HA concentra-
tion levels were significantly increased in sputum from LC
patients compared to cancer-free and healthy volunteers
(P,0.001, Figure 2A). HA levels were higher in the
sputum of patients with SqCC compared to other
histological types (P=0.01; Table 3, Figure 2B).
The sputum HA analysis capacity to distinguish
healthy volunteers from LC patients was analyzed using
an ROC curve. The area under the curve for this
condition was 0.821 (0.727-0.915). Assuming a cut-off
value of 20.06 ng/mg, the specificity was 80% and
the sensitivity was 66% (Figure 2C). The sputum
HA analysis capacity to distinguish cancer-free
patients from LC patients was analyzed by a second
ROC curve. The area under the curve for this condition
was 0.698 (0.600-0.797), and the cut-off value of
24.04 ng/mg showed 68% specificity and 60%
sensitivity (Figure 2D).
A significant correlation was found between the
biotinylated HA probe in sputum and biotinylated HA
FFPE cancer tissue (R=0.5; P=0.02).
Discussion
The first aim of this research was to evaluate the
association between malignant changes and HA through
its expression and location in tumor tissue and its
Table 2. Immunohistochemistry analysis and distribution of hyaluronan (HA) and microvessel density
(MVD) in cancer cells, stroma and peritumoral stroma stratified according to histologic types of lung cancer.
Squamous cell
carcinoma
Adenocarcinoma Large cell P
HA in cancer cells (%) ,0.001
,48% 0 (0) 10 (35.7) 4 (14.3)
>48% 9 (32.1) 5 (17.9) 0 (0)
HA in peritumoral stroma (%) 0.3
,84% 4 (14.3) 7 (25) 3 (10.7)
>84% 5 (17.9) 8 (28.6) 1 (3.6)
MVD in tumoral stroma (%) 0.02
,33% 6 (19.4) 8 (25.8) 1 (3.2)
>33% 1 (3.2) 10 (32.3) 5 (16.1)
MVD in peritumoral stroma (%) 0.5
,26% 4 (14.3) 8 (28.6) 1 (3.6)
>26% 3 (10.7) 9 (32.1) 3 (10.7)
Data are reported as the number of cases with percent in parentheses. Groups were divided as high
(>48%) and low (,48%) according to the best cut-off determined by ROC curve. The Pearson x2 test
(P,0.05) was used for statistical analyses.
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relationship with histological types, angiogenesis, and
metastases. Hypothesizing to get an association between
HA and malignant changes on prognosis, the second aim
was to evaluate whether these malignant changes were
reflected in sputum from patients with LC.
We found a significant expression of HA and micro-
vessels at the epithelial cell-extracellular matrix interface
in tumoral lung tissue, and confocal microscopy confirmed
this colocalization, suggesting that an increased synthesis
of HA occurs through interactions with HA receptors and
endothelium. HA receptors are expressed by endothelial
cells (33), lung fibroblasts, and smooth muscle (34), which
are abundant at the cell-extracellular matrix interface. This
coupled expression of HA receptors and HA at the
epithelial cell-extracellular matrix interface suggested that
these two components must interact with each other. This
interaction could play a role in attaching respiratory
epithelial cells to the basement membrane and in
maintaining their polarized morphology. When the malig-
nant transformation occurs in respiratory epithelial cells,
the imbalance between hyperexpression of HA and HA
synthases (14) is unable to attach respiratory epithelial
cells to the basement membrane, leading to invasion and
exfoliation in fluids, such as sputum. The direct associa-
tion that we found between a high percentage of HA and
microvessels in the tumor cell-stroma interface is sup-
ported by the concept that hyaluronidases (HYAL1 and
HYAL2), which are responsible for HA degradation (14),
stimulate malignant neovascularization (15) for tumor
growth and metastases. Indeed, when we analyzed the
entire tumor, we found a direct association between
tumors in T4 and N1 stages and high levels of HA in
cancer cells, clearly suggesting that surgical resection
fails to cure some patients with localized LC because of
metastases.
In the current study, a strong HA staining intensity
associated with cancer cells was also significant in SqCCs
compared to AD and LCC. Similar findings were reported
by Pirinen et al. (25), who analyzed the prognostic value
of HA in a large series of patients with non-small-cell lung
carcinoma using a biotinylated HA-specific probe. As
previously reported by Wang et al. (27), tumor cells were
enhanced in HA, but they showed considerable differ-
ences in HA expression depending on the cellular origin
as well as on the histological type of the tumor. Our
findings also support the concept that normal squamous
Figure 2. A, Box plots of hyaluronan (HA) in healthy volunteers, cancer-free patients and lung cancer patients (LC). Patients with lung
cancer had significantly higher HA levels in sputum than in the cancer-free patients and healthy volunteers (Log10 scale; P,0.001,
Mann-Whitney test). B, Box plots of HA in lung cancer patients. Patients with squamous cell carcinoma (SqCC) had higher HA levels
compared to adenocarcinoma (AD) and large cell carcinoma (LCC) (log10 scale; P,0.001, Kruskal-Wallis test). C, D, Receiver
operating characteristic (ROC) curves for sputum levels of HA. C, The cut-off level of HA that resulted in the highest diagnostic
accuracy was .31.44 ng/mg. This cut-off point discriminated between healthy controls and lung cancer patients, with 100% specificity
and 51% sensitivity. The diagnostic accuracy was 82%. D, The cut-off level of HA that discriminated cancer-free patients and lung
cancer patients with 100% specificity and 33% sensitivity was .48.3 ng/mg. The diagnostic accuracy was 69%.
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cells and carcinomas of squamous cell differentiation
mostly express large amounts of HA (29). In contrast,
tumors derived from nonstratified epithelium, such as
colon (28), ovarian (35), and breast (32) tumors, show an
absence of or a very poor HA signal. In agreement with
these reports, our present results showed a relatively low
percentage of high HA expression in AD. Likewise, our
findings showed that an elevated HA signal in tumor cells
was associated with poor prognosis, similar to results in
the literature (25,28,32,35).
Thus, we should not be surprised to learn that a
biotinylated HA-specific probe provided important prog-
nostic information about cancerous changes in tissue, and
our results now confirm the prognostic importance of HA
in LC. Whereas only four prior studies were able to show a
significant relationship between immunostaining for HA in
the tumor and survival (25,28,32,35), our results suggest
that staining for HA, used as a continuous variable,
provides more prognostic information than does routine
pathological stage. A binary cut-off point in HA in tumors
was the median of 692.1 mg/mg of cells staining for HA,
and this point provided a practical way to separate
patients into two groups: patients with an expected short
survival vs patients with an expected longer survival.
Thus, a biotinylated HA-specific probe for HA in the
primary tumor offered the potential to show malignant
changes in FFPE tissue from patients with LC.
The next question of interest was whether these
malignant changes gathered from the tumor tissue or its
milieu could help us identify patients with LC using a
noninvasive procedure such as sputum. We found that
HA concentration levels were significantly increased in
sputum from LC patients compared to cancer-free and
healthy volunteers. One of the mechanisms by which HA
increases in sputum may be via the promotion of cell
migration, because of the highly expanded, hydrated
extracellular space provided by HA, which facilitates cell
movement, and by HA signaling through its receptors
CD44 and RHAMM (36), as shown in previous studies
(34,36). As already discussed, malignant changes induce
a disproportion between expression of HA and hyalu-
ronidase by respiratory epithelial cells (14), which become
unable to attach cells to the basement membrane, leading
to exfoliation and hypersecretion of HA in sputum. Both
events lead to detachment of the HA layer that usually
covers glands and the respiratory epithelium (14). There
is another possible mechanism by which HA is deposited
in sputum. Malignant cells affect tumoral stroma remodel-
ing by regulating fibroblasts. The activated stromal
Figure 3. Kaplan-Meier plots of survival probability vs follow-up
time in months for all patients. The group with ,692.1 mg/mg HA
appears as the top curve, and the group with >692.1 mg/mg HA
appears as the bottom curve.
Table 3. Tissue and sputum hyaluronan (HA) analysis.
Tissue (mg/g) Sputum (ng/mg)
Lung cancer 713.13 ± 104.55*
Squamous cell carcinoma 808.28 ± 222.03
Adenocarcinoma 717.97 ± 135.28
Large cell carcinoma 241.7 ± 40.14
Normal lung 155.39 ± 39.28
Lung cancer 31.72 ± 2.97+
Cancer-free patients 19.78 ± 2.21
Healthy volunteers 8.72 ± 2.11
Data are reported as median±SE of HA in lung specimens from tumors and sputum. In both specimens,
determination of HA was performed using the same ‘‘ELISA-like’’ fluorometric assay. * P,0.001, HA levels
in lung cancer tissue specimens were significantly different from normal lung tissue and maintained when
categorized by histological types (P,0.001 and P=0.005).+P,0.001, HA levels in sputum of lung cancer
patients were significantly different from cancer-free patients and healthy subjects. The Mann-Whitney test
was used for statistical analyses.
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fibroblasts, termed cancer-associated fibroblasts (CAFs),
share some similarities with myofibroblasts, including the
expression of alpha smooth muscle actin (37). CAFs play
a prominent role in the remodeling process by producing
collagen and elastin fibers as well as proteoglycans and
glycoproteins (38). It has also been shown that airway
fibroblasts from LC patients produce significantly
increased concentrations of HA and HA synthase
compared to controls (4,5). LC tumors secrete tumor
necrosis factor alpha (TNF-a), tumor growth factor beta,
and endothelial growth factor, known to be potent
stimulators of HA synthesis in lung fibroblasts, and may
contribute to the deposition of HA in the airways of LC. In
addition, tumors express CD44, which binds HA, and this
interaction has been implicated in aggregation, prolifera-
tion, and migration of neoplastic cells (24,25,34).
Therefore, it is possible that LC patients express a
pathological feedback loop where tumors stimulate
fibroblast synthesis of HA through the release of tumor
growth factor beta and TNF-a, and increase recruitment of
additional fibroblasts through upregulation of CD44.
We also found that HA levels were higher in the sputum
of patients with SqCC compared to other histological types
of tumor. SqCC carcinogenesis depends on epigenetic
factors, and it has already been reported that the
connection between HA and its receptor CD44 can result
in the suppression of several epigenetic regulators and the
upregulation of survival proteins. In addition, the greater
quantities of HA in the SqCC cancer cells were reflected in
the greater quantities of HA found in the sputum from
SqCC patients in this study, and that might be explained by
the central bronchial location and squamous cell origin of
the tumor, whereas AD and LCC are located peripherally
and originate from columnar gland cells.
Previous studies have demonstrated that HA is
elevated in malignant mesothelioma effusions. In this
context, Pettersson et al. (17) found that, with the cut-off
level at 100 mg/L, the pleural fluid concentration of HA was
increased in 73% of patients with mesothelioma and 23%
of patients with nonmalignant inflammatory diseases, but in
none of the patients with cancer other than mesothelioma
and in none of the patients with congestive heart failure.
Other studies have demonstrated that HA is elevated in
urine from patients with urologic cancer. Lokeshwar et al.
(39) compared levels of HA in the urine of normal
individuals and patients with bladder cancer or other
genitourinary conditions, and found that the urinary HA
measurement by the ELISA-like assay shows a sensitivity
of 91.9% and specificity of 92.8% to detect bladder cancer.
In inflammatory conditions, such as chronic obstructive
pulmonary disease and asthma, HA has also been applied
for diagnostic purposes in sputum. Ayars et al. (30)
examined levels of HA in the sputum of asthmatics treated
with mepolizumab therapy vs those taking a placebo, and
found reduced levels of HA as well as improved clinical and
spirometry values in the patients treated with mepolizu-
mab, suggesting that this measurement may serve as a
noninvasive biomarker of asthma control.
To our knowledge, the current study is the first to
investigate HA as an indicator in the sputum from patients
with LC, therefore limiting a comparison of the results,
unless they are compared to the current gold standard,
sputum cytology. Presently, sputum cytology is the
minimum invasive resource for obtaining a diagnosis in
a patient who is suspected of having LC. However, the
diagnostic accuracy of sputum cytology depends on
rigorous specimen sampling and preservation techniques,
as well as on the location and size of the tumor (central vs
peripheral). In the present study, we showed that, using a
single low-cost procedure that is not time consuming and
that can be performed routinely in the lab, sputum HA
distinguished tumor patients from those without tumor
with 80% specificity and 66% sensitivity. Similarly, the
sputum HA concentration can distinguish cancer-free
patients from LC patients with 68% specificity and 60%
sensitivity. According to the literature, sputum cytology
sensitivity ranges from 42% to 97% and specificity ranges
from 68 to 100% (40). Our findings contrast with a recent
study published by Van Rensburg et al. (31) in which the
sputum cytology in a high-risk population revealed a
sensitivity of 38.9% to detect malignant cells and 100%
accuracy. Comparing our findings to the literature, we
presume that the sensitivities between 60% and 66% that
we found can be within the same limits of variation as
cytology sputum. Therefore, HA evaluation in sputum
could be superior or similar to the current gold standard,
sputum cytology, eventually emphasizing that combined
sputum HA and cytology may add considerably to the
diagnostic armamentarium currently used in the clinic for
LC diagnosis.
Localization of HA in tumor tissue and its relationship
with histological types and angiogenesis was related to
malignancy of LC and reflected in sputum, which is
emerging as an important diagnostic procedure in patients
with suspicion of LC. To confirm these results, more
studies in a randomized and prospective trial are needed,
and we also believe it is important to validate our
quantitative assessment of HA and to couple it to gold
standard sputum cytology by studying HA in additional
patients.
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